One of the main causes of severe diabetic heart failure and mortality is diabetic cardiomyopathy (DCM), a cardiovascular condition attributable to diabetes with a high incidence, a complicated and unexplained pathophysiology, and poor treatment results. Current findings have demonstrated that the onset of diabetic cardiomyopathy involves autophagy, inflammation, and mitochondrial damage. Myocardial autophagy behaves differently in different states,and one of the targets for the detection and treatment of cardiovascular illnesses like diabetic cardiomyopathy may be the control of autophagy. The role of human umbilical cord Mesenchymal stem cells-derived exosomes (HUCMSC-EXO) as a non-cellular system in the repair of cardiomyocytes, the evolution of diabetic cardiomyopathy and their cardioprotective effects are gradually being recognized. This study's objectives were to assess the therapeutic benefits of HUCMSC-EXO for diabetic cardiomyopathy and to look into their potential mechanisms of action. High-speed centrifugation was used to extract HUCMSC-EXO, and the shape of the exosomes was examined using transmission electron microscopy. Immunoblotting was used to determine the expression of CD9, CD63, and TSG101 molecules on the surface of the exosomes. A high-fat, high-sugar diet mixed with streptozotocin was used to build a rat model of type 2 diabetic cardiomyopathy. Cardiac function, ventricular wall thickness and cardiac histological changes were examined by cardiac ultrasound, serum BNP and histology. In cardiac myocytes, HUCMSC-EXO reduced the levels of autophagy-related protein expression. Additionally, immunoblotting supported our suspicion that this mechanism is strongly tied to the activation of the AMPK-ULK1 signaling pathway. So, we propose that it would be a good strategy to follow for treating diabetic cardiomyopathy. These findings offer both fresh concepts for building a model of diabetic cardiomyopathy and a creative theoretical framework for using HUCMSC-EXO to treat diabetic cardiomyopathy in a clinical setting.
21 April 2025 in IEEE Transactions on Biomedical Engineering
Accurate segmentation of prostate tumors from multi-modal magnetic resonance (MR) images is crucial for the diagnosis and treatment of prostate cancer. However, the robustness of existing segmentation methods is limited, mainly because these methods 1) fail to flexibly assess subject-specific information of each MR modality and integrate modality-specific information for accurate tumor delineation, and 2) lack effective utilization of inter-slice information across thick slices in MR images to segment the tumor as a whole 3D volume. In this work, we propose a neighbor-sensitive multi-modal flexible learning network (NesMFle) for accurate prostate tumor segmentation from multi-modal anisotropic MR images. Specifically, we perform multi-modal fusion for each slice by developing a Modality-informativeness Flexible Learning (MFLe) module for selecting and flexibly fusing informative representations of each modality based on inter-modality correlation in a pre-trained manner. After that, we exploit inter-slice feature correlation to derive volumetric tumor segmentation. In particular, we first use a Unet variant equipped with a Sequence Layer, which can coarsely capture slice relationship using 3D convolution and an attention mechanism. Then, we introduce an Activation Mapping Guidance (AMG) module to refine slice-wise representations using information from adjacent slices, ensuring consistent tumor segmentation across neighboring slices based on slice quality assessment on activation maps. Besides, during the network training, we further apply a random mask strategy to each MR modality for improving feature representation efficiency. Experiments on both in-house and public (PICAI) multi-modal prostate tumor datasets demonstrate that our proposed NesMFLe achieves competitive performance compared to state-of-the-art methods.
MultiRecNet, a fully automatic multitask deep learning network, accurately predicted disease-free survival in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy, using multimodal MRI.